Virtu Financial LLC Immuno Gen, Inc. Transaction History

Virtu Financial LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $120,289 - $157,909	-23,962 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$5.79 - $8.6 $138,739 - $206,073	23,962 New	23,962 $158,000
Q1 2021 May 19, 2021	SELL	$6.5 - $10.53 $72,904 - $118,104	-11,216 Closed	0 $0
Q4 2020 Feb 24, 2021	SELL	$3.7 - $7.66 $229,533 - $475,195	-62,036 Reduced 84.69%	11,216 $72,000
Q3 2020 Dec 11, 2020	BUY	$3.45 - $4.89 $252,719 - $358,202	73,252 New	73,252 $264,000
Q2 2020 Aug 07, 2020	SELL	$3.32 - $5.34 $229,239 - $368,716	-69,048 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$2.25 - $5.8 $1,118 - $2,882	497 Added 0.73%	69,048 $352,000
Q3 2019 Nov 20, 2019	SELL	$2.22 - $3.39 $37,537 - $57,321	-16,909 Reduced 19.79%	68,551 $166,000
Q2 2019 Aug 13, 2019	BUY	$1.8 - $3.3 $105,100 - $192,683	58,389 Added 215.69%	85,460 $185,000
Q1 2019 Apr 12, 2019	BUY	$2.41 - $5.91 $65,241 - $159,989	27,071 New	27,071 $73,000
Q2 2018 Jul 30, 2018	SELL	$9.52 - $12.15 $603,853 - $770,674	-63,430 Closed	0 $0
Q2 2018 Jul 30, 2018	SELL	$9.52 - $12.15 $17,811 - $22,732	-1,871 Reduced 2.87%	63,430 $617,000
Q1 2018 May 14, 2018	BUY	$6.7 - $12.95 $437,516 - $845,647	65,301 New	65,301 $687,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.